お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
736690

酒さ:市場洞察、疫学、市場予測

Rosacea - Market Insight, Epidemiology and Market Forecast - 2028

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
酒さ:市場洞察、疫学、市場予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における酒さの有病数は2016年に4,735万9,758人、市場規模は4億9,440万米ドルと推計されています。

当レポートでは、酒さについて調査し、疾患の概要、患者背景、主要7カ国における性別・種類・重症度別の有病数および診断数、治療薬別の市場規模の推移と予測(今後10年間分)、上市済み薬および新薬の概要、診断ガイドライン、市場規模、市場の成長要因・障壁、競合情勢などを包括的にまとめています。

目次

第1章 重要な洞察

第2章 酒さ:市場概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 兆候と症状
  • 酒さの分類
  • 病状と重症度
  • 病態生理
  • ゲノムワイド関連解析(GWAS)に基づく遺伝的背景
  • 原因と危険因子
  • 診断

第4章 疫学と患者人口

  • 主な所見

第5章 主要7カ国の総有病数

第6章 主要7カ国の総診断数

第7章 酒さの疫学:国別

  • 米国
    • 前提と根拠
    • 総有病数
    • 有病数:性別
    • 総診断数
    • 診断数:種類別
    • 診断数:重症度別
  • 欧州主要5カ国
    • ドイツ
      • 総有病数
      • 有病数:性別
      • 総診断数
      • 診断数:種類別
      • 診断数:重症度別
    • フランス
      • 総有病数
      • 有病数:性別
      • 総診断数
      • 診断数:種類別
      • 診断数:重症度別
    • イタリア
      • 総有病数
      • 有病数:性別
      • 総診断数
      • 診断数:種類別
      • 診断数:重症度別
    • スペイン
      • 総有病数
      • 有病数:性別
      • 総診断数
      • 診断数:種類別
      • 診断数:重症度別
    • 英国
      • 総有病数
      • 有病数:性別
      • 総診断数
      • 診断数:種類別
      • 診断数:重症度別
  • 日本
    • 総有病数
    • 有病数:性別
    • 総診断数
    • 診断数:種類別
    • 診断数:重症度別

第8章 治療アルゴリズム、現行治療、医療行為

第9章 アンメットニーズ

第10章 上市済み薬

  • Rhofade:Allergan
    • 薬品概要
    • 作用機序
    • 規制のマイルストーン
    • 製品開発の動向
    • 長所と短所
    • 安全性と有効性
    • 製品プロファイル
  • Oracea:Galderma Laboratories
  • Mirvaso:Galderma Laboratories
  • Finacea:Bayer
  • Soolantra:Galderma Laboratories, Inc.
  • Metrogel:Galderma Laboratories

第11章 キークロスコンペティション

第12章 新薬

  • FMX103:Foamix Pharmaceuticals
    • 薬品概要
    • 作用機序
    • 規制のマイルストーン
    • 製品開発の動向
    • 長所と短所
    • 安全性と有効性
    • 製品プロファイル
  • Epsolay:Sol-Gel
  • Omiganan:Cutanea Life Sciences
  • BPX-04:BioPharmX, Inc.
  • ACU-D1:Accuitis., Inc.
  • HY01(Minocycline):Hovione Scientia Limited
  • DFD-04:Dr. Reddy's Laboratories
  • DFD-29:Dr. Reddy's Laboratories
  • DMT210:Dermata Therapeutics

第13章 主要7カ国市場の分析

  • 主な所見
  • 主要7カ国の市場規模

第14章 米国市場の見通し

  • 米国の市場規模
    • 総市場規模
    • 市場規模:治療薬別

第15章 欧州5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
    • 総市場規模
    • 市場規模:治療薬別
  • イタリア
    • 総市場規模
    • 市場規模:治療薬別
  • スペイン
    • 総市場規模
    • 市場規模:治療薬別
  • 英国
    • 総市場規模
    • 市場規模:治療薬別

第16章 日本市場の見通し

  • 総市場規模
  • 市場規模:治療薬別

第17章 市場の成長要因

第18章 市場の障壁

第19章 付録

  • 調査方法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Table 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Table 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Table 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Table 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Table 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Table 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Table 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Table 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Table 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Table 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Table 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Table 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Table 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Table 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Table 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Table 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Rosacea in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Rosacea in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Rosacea in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Rosacea in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Rosacea in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Rosacea in United States (2016-2028)
  • Figure 7: Treatable Cases of the Rosacea in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Rosacea in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Rosacea in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Rosacea in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Rosacea in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Rosacea in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Rosacea in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Rosacea in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Rosacea in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Rosacea in France (2016-2028)
  • Figure 17: Treatable Cases of the Rosacea in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Rosacea in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Rosacea in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Rosacea in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Rosacea in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Rosacea in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Rosacea in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Rosacea in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Rosacea in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Rosacea in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Rosacea in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Rosacea in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Rosacea in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Rosacea in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Rosacea in UK (2016-2028)
  • Figure 32: Treatable Cases of the Rosacea in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Rosacea in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Rosacea in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Rosacea in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Rosacea in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Rosacea in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Rosacea in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 45: United States-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 51: France-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 60:UK-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Rosacea in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Rosacea by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Rosacea by Therapies in USD MM (2016-2028)
目次
Product Code: DIMI0199

DelveInsight's "Rosacea - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Rosacea epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Rosacea Understanding and Treatment Algorithm

The market report provides the overview of the Rosacea by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Rosacea Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Rosacea in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Rosacea Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Rosacea Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Rosacea market.

Rosacea Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Rosacea Report Insights

  • Patient Population in Rosacea
  • Therapeutic Approaches in Rosacea
  • Rosacea Pipeline Analysis
  • Rosacea Market Size and Trends
  • Rosacea Market Opportunities
  • Impact of upcoming Therapies in Rosacea

Rosacea Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Rosacea Report Assessment

  • Current Treatment Practices in Rosacea
  • Unmet Needs in Rosacea
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Rosacea market
  • Organize sales and marketing efforts by identifying the best opportunities for Rosacea market
  • To understand the future market competition in the Rosacea market.

Table of Contents

1. Report Introduction

2. Rosacea Market Overview at a Glance

  • 2.1. Market Share Distribution of Rosacea in 2016
  • 2.2. Market Share Distribution of Rosacea in 2028

3. Disease Background and Overview: Rosacea

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Rosacea in 7MM
  • 4.3. Total Prevalent Patient Population of Rosacea in 7MM - By Countries

5. Epidemiology of Rosacea by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Rosacea
    • 5.1.3. Sub-Type Specific cases of the Rosacea *
    • 5.1.4. Sex- Specific Cases of the Rosacea *
    • 5.1.5. Diagnosed Cases of the Rosacea
    • 5.1.6. Treatable Cases of the Rosacea
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Rosacea
    • 5.4.3. Sub-Type Specific cases of the Rosacea *
    • 5.4.4. Sex- Specific Cases of the Rosacea *
    • 5.4.5. Diagnosed Cases of the Rosacea
    • 5.4.6. Treatable Cases of the Rosacea
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Rosacea
    • 5.5.3. Sub-Type Specific cases of the Rosacea *
    • 5.5.4. Sex- Specific Cases of the Rosacea *
    • 5.5.5. Diagnosed Cases of the Rosacea
    • 5.5.6. Treatable Cases of the Rosacea
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Rosacea
    • 5.6.3. Sub-Type Specific cases of the Rosacea *
    • 5.6.4. Sex- Specific Cases of the Rosacea *
    • 5.6.5. Diagnosed Cases of the Rosacea
    • 5.6.6. Treatable Cases of the Rosacea
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Rosacea
    • 5.7.3. Sub-Type Specific cases of the Rosacea *
    • 5.7.4. Sex- Specific Cases of the Rosacea *
    • 5.7.5. Diagnosed Cases of the Rosacea
    • 5.7.6. Treatable Cases of the Rosacea
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Rosacea
    • 5.8.3. Sub-Type Specific cases of the Rosacea *
    • 5.8.4. Sex- Specific Cases of the Rosacea *
    • 5.8.5. Diagnosed Cases of the Rosacea
    • 5.8.6. Treatable Cases of the Rosacea
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Rosacea
    • 5.9.3. Sub-Type Specific cases of the Rosacea *
    • 5.9.4. Sex- Specific Cases of the Rosacea *
    • 5.9.5. Diagnosed Cases of the Rosacea
    • 5.9.6. Treatable Cases of the Rosacea

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Rosacea

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Rosacea

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Rosacea : 7MM Market Analysis

  • 12.1. 7MM Market Size of Rosacea
  • 12.2. 7MM Percentage Share of drugs marketed for Rosacea
  • 12.3. 7MM Market Sales of Rosacea by Products

13. Rosacea : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Rosacea in United States
    • 13.1.2. Percentage Share of drugs marketed for Rosacea in United States
    • 13.1.3. Market Sales of Rosacea by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Rosacea in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Rosacea in Germany
      • 13.2.1.3. Market Sales of Rosacea by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Rosacea in France
      • 13.2.2.2. Percentage Share of drugs marketed for Rosacea in France
      • 13.2.2.3. Market Sales of Rosacea by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Rosacea in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Rosacea in Italy
      • 13.2.3.3. Market Sales of Rosacea by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Rosacea in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Rosacea in Spain
      • 13.2.4.3. Market Sales of Rosacea by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Rosacea in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Rosacea in United Kingdom
      • 13.2.5.3. Market Sales of Rosacea by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Rosacea in Japan
    • 13.3.2. Percentage Share of drugs marketed for Rosacea in Japan
    • 13.3.3. Market Sales of Rosacea by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.